Abstract:Background Re-capture of the differences between tumor and normal tissues observed at the patient level in cell cultures and animal models is critical for applications of these cancer-related differences. The epithelial-mesenchymal transition (EMT) process is essential for tumor migratory and invasive capabilities. Although plenty of EMT markers are revealed, molecular features during the early stages of EMT are poorly understood. Methods A cell-based model to induce lung cell (A549) EMT using conditioned medium of in vitro cancer activated fibroblast (WI38) was established. High-throughput sequencing methods, including RNA-seq and miRNA-seq, and advanced bioinformatics methods were used to explore the transcriptome profile transitions accompanying the progression of EMT. We validated our findings with experimental techniques including transwell and immunofluorescence assay, as well as the TCGA data. Results We have constructed an in vitro cell model to mimic the EMT in patients. We discovered that several new transcription factors were among the early genes (3 h) to respond to cancer micro-environmental cues which could play critical roles in triggering further EMT signals. The early EMT markers also included genes encoding membrane transporters and blood coagulation function. Three of the nine-examined early EMT hallmark genes, GALNT6, SPARC and HES7, were up-regulated specifically in the early stages of lung adenocarcinoma (LUAD) and confirmed by TCGA patient transcriptome data. In addition, we showed that miR-3613, a regulator of EGFR pathway genes, was constantly repressed during EMT progress and indicative of an epithelial miRNA marker. Conclusions The CAF-stimulated EMT cell model may recapture some of the molecular changes during EMT progression in clinical patients. The identified early EMT hallmark genes GALNT6, SPARC and HES7and miR-3613 provide new markers and therapeutic targets for LUAD for the further clinical diagnosis and drug screening.

The Landscape of Histone Acetylation Involved in Epithelial-Mesenchymal Transition in Lung Cancer

Regulation of epithelial-mesenchymal transition by protein lysine acetylation

Epigenetic Control of Epithelial-to-mesenchymal Transition and Cancer Metastasis

Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities

Epigenetic Regulation of Epithelial to Mesenchymal Transition.

Epigenetic modification regulates tumor progression and metastasis through EMT (Review)

Histone Modifications Represent a Key Epigenetic Feature of Epithelial-to-Mesenchyme Transition in Pancreatic Cancer

Histone acetyltransferase CSRP2BP promotes the epithelial–mesenchymal transition and metastasis of cervical cancer cells by activating N-cadherin

Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer

Epithelial–Mesenchymal Transition in Acute Leukemias

Aspects of the Epigenetic Regulation of EMT Related to Cancer Metastasis

Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy

Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells

Whole DNA Methylome Profiling in Lung Cancer Cells Before and after Epithelial-to-mesenchymal Transition.

Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis

Epithelial-mesenchymal Transition Markers Screened in a Cell-Based Model and Validated in Lung Adenocarcinoma

Roles and epigenetic regulation of epithelial–mesenchymal transition and its transcription factors in cancer initiation and progression

Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial-mesenchymal plasticity and tumor metastasis

New Insights into the Epithelial-to-Mesenchymal Transition in Cancer

Global Histone Modification Profiling Reveals the Epigenomic Dynamics During Malignant Transformation in a Four-Stage Breast Cancer Model

Missing Links in Epithelial-Mesenchymal Transition: Long Non-Coding RNAs Enter the Arena.